Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) Receives Consensus Rating of 'Moderate Buy'

Shares of Kestra Medical Technologies, Ltd. (NASDAQ:KMTS - Get Free Report) have received a consensus recommendation of "Moderate Buy" from six analysts monitoring the stock, as reported by MarketBeat. Among these analysts, one has assigned a hold rating while the remaining five have given the stock a buy recommendation. The average target price set by analysts for the next year is $27.67.

Recently, several equity research analysts expressed their views about Kestra Medical Technologies. Wells Fargo & Company initiated coverage on the stock and assigned it an "overweight" rating along with a target price of $28.00. Similarly, Wolfe Research also began coverage, issuing an "outperform" rating and a price objective of $29.00. Piper Sandler joined the ranks of analysts covering Kestra Medical, setting an "overweight" rating with a target of $27.00. Stifel Nicolaus rated the stock as a "buy" with a price objective of $28.00. Lastly, The Goldman Sachs Group initiated coverage with a "neutral" rating and a $24.00 target price.

Kestra Medical Technologies Price Performance

During mid-day trading on Monday, shares of NASDAQ KMTS saw a slight increase of $0.02, reaching $23.45. Approximately 44,548 shares changed hands, which is lower than its average trading volume of 290,871. Over the past twelve months, the stock recorded a low of $20.00 compared to its high of $25.98.

Kestra Medical Technologies Company Overview

Kestra Medical Technologies is a company engaged in commercial-stage operations, focusing on wearable medical devices and digital healthcare solutions. Their primary goal is to enhance patient outcomes in cardiovascular health through advanced monitoring and therapeutic intervention technologies that are user-friendly, smart, and connected. They are currently working on the commercialization of their Cardiac Recovery System platform, which brings together monitoring, treatment, digital health, and patient support into one integrated offering.

Investment Considerations

Investors considering a stake in Kestra Medical Technologies might want to weigh their options. MarketBeat indicates that while the stock enjoys a Moderate Buy rating from several analysts, there are other stocks recommended by top analysts that may present better investment opportunities.

stocks, analysis, recommendation